Powder: -20°C for 3 years
In solvent: -80°C for 2 years
FLT3-IN-13 (compound 20) is a highly effective inhibitor targeting both topoisomerase II and FLT3 proteins in leukemic cells. It exhibits potent activity against these targets, with IC50 values of 2.26 μM for both. Moreover, FLT3-IN-13 induces cell cycle arrest at the G2/M phase and promotes apoptosis. Notably, it displays considerable anticytotoxic activity, specifically against leukemia [1].
Description | FLT3-IN-13 (compound 20) is a highly effective inhibitor targeting both topoisomerase II and FLT3 proteins in leukemic cells. It exhibits potent activity against these targets, with IC50 values of 2.26 μM for both. Moreover, FLT3-IN-13 induces cell cycle arrest at the G2/M phase and promotes apoptosis. Notably, it displays considerable anticytotoxic activity, specifically against leukemia [1]. |
In vitro | FLT3-IN-13 (compound 20) has strong antiproliferative activity against HL-60 with an IC 50 of 0.48 ± 0.08 μM [1]. FLT3-IN-13 arrests HL-60 cell cycle at G2/M phase (G1%: 24.76±1.00, S%: 21.26±1.72, G2%: 32.78±2.21, total apoptosis%: 21.36±2.73) [1]. FLT3-IN-13 induces apoptosis of HL-60 with early-apoptosis of 6.13±1.20% and late-apoptosis of 13.06±0.40% [1]. FLT3-IN-13 significantly upregulates P53, TNFα and caspase 3/7 proteins in the HL-60 cell line, and increases the Bax/Bcl-2 ratio [1]. |
Molecular Weight | 342.35 |
Formula | C20H14N4O2 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
FLT3-IN-13 Inhibitor inhibitor inhibit